Clinical Trial Update: A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating the combination of tagraxofusp with venetoclax and azacitidine in adults with untreated CD123+ acute myeloid leukemia who cannot u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Elzonris (tagraxofusp)
• VIDAZA (AZACITIDINE)
• Venclexta (venetoclax)

Snippet

Sponsor: Stemline Therapeutics, Inc. | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING